An interventional study of Active taVNS and Sham taVNS in Lipedema, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Lipedema with a site in Turkey — 18 open to participants now, 19 under way, none of them phase 3. Lipedema · Turkey.
Among the 41 studies in Lipedema with a site in Turkey, this one is the 11th largest by planned enrollment of the 14 interventional ones that give a count, is one of 17 that started in 2026, is one of 14 with no phase, reaches primary completion later than 18 of the 18 other live ones, and was the 38th registered.
85 studies on the registry are indexed under Lipedema; 31 are open to participants now.
Browse Lipedema studies →18 of the 41 studies in Lipedema with a site in Turkey are open now. Recruiting first, the newest first:
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
Ages 18–65 · Women only · Healthy volunteers
Hitit University · Sites in Turkey
Ages 18–65
Hatice Zehra FERHATLAR · Sites in Turkey
Ages 18–65 · Women only
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–65 · Women only
Merve SEVINC GUNDUZ · Sites in Turkey
Ages 18–65 · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 18 Lipedema studies recruiting now, 3 (17%) set no upper age limit and 15 (83%) stop at 75 or younger; none take children under 18; 4 take healthy volunteers.
This study: 18 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 17 started in 2026.
This study's planned enrollment of 30 is below the median of 35 across 42 interventional studies indexed under Lipedema.
Median enrollment 37 across the 14 interventional studies, 76 across the 27 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 41 has an industry lead sponsor. The 10 most frequent:
Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.
Istanbul University - Cerrahpasa has 2 studies filed under Lipedema — fewer than ten, so there is no comparison to draw.
9 of the studies in Lipedema with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07683559Atlas UniversityExtracorporeal Shock Wave Therapy in Patients With Lipedema | 2026-12-01 |
| NCT07919574Hatice Zehra FERHATLAREffectiveness of Kinesio Taping as an Adjunct to Conservative Treatment in Women With Lipedema | 2027-01-15 |
| NCT07803926Merve SEVINC GUNDUZManual and Self-Lymphatic Drainage Combined With Exercise in Women With Lipedema | 2027-01-20 |
| NCT07468097Marmara UniversityThe Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational Study | 2027-02-01 |
| NCT07725146Marmara UniversityTurkish Validation of the Rapprich Lipedema Symptomatic Assessment Questionnaire | 2027-02-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 41 studies in Lipedema with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Lipedema is a chronic inflammatory disorder of adipose tissue that predominantly affects women and is associated with estrogen-mediated mechanisms. [1] Conservative physiotherapy approaches, including exercise, compression therapy, complex decongestive therapy (CDT), and behavioral interventions, are recommended for the management of lipedema. [2,3] Transcutaneous auricular vagus nerve stimulation (taVNS) is a neuromodulation method that may reduce pro-inflammatory cytokines through the cholinergic anti-inflammatory pathway and exert metabolic and autonomic regulatory effects. [4] These effects suggest that taVNS may serve as a complementary intervention to exercise and conservative physiotherapy approaches in the management of chronic low-grade inflammation, one of the pathophysiological components of lipedema. In light of this evidence, the aim of this study is to comparatively investigate the effects of taVNS-enhanced rehabilitation versus conventional rehabilitation on lower extremity function, pain, and quality of life in individuals with lipedema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
taVNS + Aerobic Exercise + Complex Decongestive Therapy (CDT)
Device: Active taVNS · Other: Aerobic Exercise · Other: Complex Decongestive Therapy (CDT)
Sham taVNS + Aerobic Exercise + Complex Decongestive Therapy (CDT)
Device: Sham taVNS · Other: Aerobic Exercise · Other: Complex Decongestive Therapy (CDT)
Active taVNS will be administered concurrently with aerobic exercise for 30 minutes per session, twice weekly for six weeks. Electrical stimulation will be delivered to the auricular region using a transcutaneous vagus nerve stimulation device.
Sham taVNS will be administered concurrently with aerobic exercise for 30 minutes per session, twice weekly for six weeks. The sham procedure will be performed using the auricular stimulation device without sustained therapeutic electrical stimulation.
Participants in both groups will receive supervised moderate-intensity treadmill-based aerobic exercise concurrently with active or sham taVNS. Aerobic exercise will be administered for 30 minutes per session, twice weekly for six weeks.
Participants in both groups will receive complex decongestive therapy for 30 minutes per session, twice weekly for six weeks, following the concurrent aerobic exercise and active or sham taVNS intervention.
Change in Pain Intensity
Pain intensity will be assessed using the Numerical Pain Rating Scale (NPRS), an 11-point self-reported scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in NPRS scores from baseline to week 6 will be evaluated.
Time frame: Baseline and week 6
Change in Lower Extremity Volume
Lower extremity volume will be assessed bilaterally using circumferential measurements taken at standardized intervals with a non-elastic measuring tape. Total limb volume will be calculated using the truncated cone (frustum) formula. Changes in limb volume from baseline to week 6 will be evaluated. Results will be expressed in milliliters (mL).
Time frame: Baseline and week 6
Change in Body Composition
Body composition will be assessed using bioelectrical impedance analysis (BIA). Measurements will include fat mass, fat-free mass, total body water, and the leg-to-arm impedance ratio. Changes in these parameters from baseline to week 6 will be evaluated.
Time frame: Baseline and week 6
Change in Heart Rate Variability
Heart rate variability (HRV) will be assessed using a Polar H10 heart rate monitor, with data analyzed using the Elite HRV application. Time-domain and frequency-domain parameters, including mean RR interval, SDNN, RMSSD, ln(RMSSD), pNN50, LF power, HF power, LF/HF ratio, LF peak, HF peak, and total power, will be evaluated. Changes from baseline to week 6 will be assessed.
Time frame: Baseline and week 6
Change in Lower Extremity Functional Status
Description: Lower extremity functional status will be assessed using the Lower Extremity Functional Scale (LEFS), a 20-item questionnaire evaluating difficulty in performing daily activities. Each item is scored from 0 to 4, yielding a total score ranging from 0 to 80. Higher scores indicate better lower extremity function. Changes from baseline to week 6 will be evaluated.
Time frame: Baseline and week 6
Change in Functional Capacity
Description: Functional capacity will be assessed using the Six-Minute Walk Test (6MWT), conducted along a 30-meter indoor corridor. The total distance walked in six minutes will be recorded in meters. Changes in walking distance from baseline to week 6 will be evaluated.
Time frame: Baseline and week 6
Change in Health-Related Quality of Life
Description: Health-related quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36), which evaluates eight health domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Each domain is scored from 0 to 100, with higher scores indicating better health status. Changes from baseline to week 6 will be evaluated.
Time frame: Baseline and week 6
Patient-Perceived Global Change
Description: Patient-perceived change will be assessed using the Global Rating of Change (GRC) Scale, a five-point Likert-type scale ranging from -2 (much worse) to +2 (much better), with 0 indicating no change. Participants will rate their perceived change compared with their pretreatment status.
Time frame: Week 6 (to be confirmed)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.
Of 29 interventional studies with no phase under Lipedema, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 16 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University - Cerrahpasa →